Please login to the form below
Usona Institute
This page shows the latest Usona Institute news and features for those working in and with pharma, biotech and healthcare.
Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
Eleusis’ trial comes after the non-profit Usona Institute launched a phase 2 trial of psilocybin – found in ‘magic mushrooms’ – as a treatment for major depressive disorder.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Scientists discover new approach to treat brain tumours
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- Almirall and Evotec team up in multi-target dermatology alliance
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Kim Lemon appointed head of Liberation Unlimited
- Perrigo expands consumer health with €3.6bn Omega purchase
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
